Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 8/20 | 0.39 |
| ▸ | PDCD1LG2 | Q9BQ51 | 3/20 | 0.36 |
| ▸ | CD274 | Q9NZQ7 | 3/20 | 0.36 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.36 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.36 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.35 |
| ▸ | PTGES | O14684 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CTSA | P10619 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4015180 | 1.00 | MAPK14 (0.39) | MAPK14PDCD1LG2CD274MAPK11CARM1 | |
| SCHEMBL4020089 | 0.88 | SLC6A2 (0.45) | MAPK14MAPK11TRPA1 | |
| SCHEMBL4019146 | 0.87 | TRPA1 (0.41) | MAPK14MAPK11TRPA1SMN1; SMN2CTSA | |
| SCHEMBL4014863 | 0.84 | TGFBR1 (0.40) | MAPK14MAPK11CARM1PRMT6CTSA | |
| SCHEMBL4015352 | 0.82 | TRPA1 (0.41) | MAPK14MAPK11TRPA1 | |
| SCHEMBL4014032 | 0.81 | TRPA1 (0.45) | MAPK14TRPA1CTSA | |
| SCHEMBL5097216 | 0.81 | MAPK14 (0.42) | MAPK14MAPK11TRPA1 | |
| SCHEMBL4014052 | 0.80 | MAPK14 (0.37) | MAPK14MAPK11CARM1PRMT6TRPA1 | |
| SCHEMBL14019123 | 0.80 | MAPK14 (0.37) | MAPK14MAPK11CARM1PRMT6TRPA1 | |
| SCHEMBL4014041 | 0.80 | MAPK14 (0.37) | MAPK14MAPK11CARM1PRMT6TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7566708-B2 | Substituted pyrazolo{3,4-D}pyrimidines as p38 map kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2009-07-28 | — | — | US | disclosed |
| US-7566708-B2 | Substituted pyrazolo{3,4-D}pyrimidines as p38 map kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2009-07-28 | — | — | US | disclosed |
| US-20070203160-A1 | p38 MAP kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC | 2007-08-30 | — | — | US | disclosed |
| US-20070203160-A1 | p38 MAP kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203160-A1 | p38 MAP kinase inhibitors and methods for using the same | MAPKAPK2, MAPK1, MAP3K2 | MAPK14 33/4885PDCD1LG2 3101/4885CD274 4397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.